SOTIO to trial SOT101 alongside Keytruda

8 December 2021

Czech immuno-oncology (I-O) specialist SOTIO Biotech, part of the investment company PPF Group, has entered into a clinical trial collaboration and supply agreement with Merck & Co (NYSE: MRK), the US pharma giant known as MSD outside North America.

The trial will evaluate the combination of SOT101, SOTIO’s interleukin (IL)-15 superagonist, and Merck’s Keytruda (pembrolizumab), in patients with selected advanced/refractory solid tumors in the Phase II AURELIO-04 study.

"SOT101 in combination with Keytruda has shown promising clinical efficacy across multiple indications in our ongoing Phase I/Ib AURELIO-03 study"Radek Špíšek, global chief executive of SOTIO, said: “SOT101 in combination with Keytruda has shown promising clinical efficacy across multiple indications in our ongoing Phase I/Ib AURELIO-03 study.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK